A Phase I, Double Blind, Placebo-controlled, Randomized, Parallel, Single Ascending Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of AMG 592 Administered Subcutaneously in Healthy Japanese Subjects
Latest Information Update: 05 Jun 2023
At a glance
- Drugs Efavaleukin alfa (Primary)
- Indications Graft-versus-host disease
- Focus Pharmacokinetics
- Sponsors Amgen
Most Recent Events
- 05 Jun 2023 New trial record